In fact, in only one quarter between 2013 and 2015 did you report that growth was driven by volume, so price increases has, in fact, been the entree for your business, correct?
Claire McCaskill
The Public Record
Claire McCaskill is an American politician and attorney who served as the United States Senator from Missouri from 2007 to 2019. She was the first woman elected to the Senate from Missouri. A member of the Democratic Party, McCaskill focused on issues such as healthcare, military support, and government accountability during her tenure in the Senate. She played a significant role in various legislative efforts and was known for her outspoken views on military contracting and defense spending.
Well, we are in trouble if you are---over the last year, with everything that has gone on in the company, if you are 78 percent over last year in the top 30 selling drugs, if you are an industry leader in this area, we are going to have to…
Well, wouldn't you have done due diligence on this as you were deciding to invest more and more--you kept investing.
You were very involved after you started--when you did your SEC filing in March, you were sending emails back and forth in July giving them PR advice, approving press releases.
I am glad to be here today for the third of our series of hearings about rising drug prices.
I know that the Post Office is more important than the brick and mortar in terms of that community in the sense of community.
It seems like to me we should charge them extra for the most expensive part of our architecture.
I think we are getting taken, and I think this happened because there was a panic about the drop in First Class Mail.
Maybe, we figure out what the price is to buy the drug that we paid to develop and continue to manufacture it ourselves and drive that cost way down.
It seems weird that we are making the investment and then they can profit off of theirs for the life of the company.
Most people in Missouri do not understand that--why we would pay for the development of a drug and then have to pay $3,000 a pop for the drug after we paid to develop it.
Metrics matter. And, the idea that we are spending--just in that one example--$100 million in Honduras on an anti-gang problem and the problem has gotten exponentially worse as opposed to better.
Have we gone down the rabbit hole so far that we do not realize how silly this has gotten?
I cannot think of another disease that is more deserving of the increased research dollars.
I urge the Congress to consider this important legislation that will not only benefit those living with Alzheimer's and their caregivers but will actually save the government money.
If we have certain standards for safety and security for our flying public, and the responsibility lies with your agency and the FAA to make sure that the standards are just as rigorous.
I would urge you to ask your Representatives in the House to pass the RAISE Act without further delay.





